Abstract
Regenerative Medicine, a recent new medical domain, aims to develop new therapies through the stimulation of natural regenerative processes also in human beings. In this field, Erythropoietin (EPO) represents a significant subject of research. Several studies allow the assertion that EPO, in different concentrations, has protective effects mainly on the central nervous system, cardiovascular system and renal tissue. This action is carried out through one of few regenerative activities of human beings: angiogenesis. This mechanism, which involves endothelial stem cells and VEGF (Vascular Endothelial Growth Factor), has been experimentally demonstrated with Recombinant human erythropoietin (rHuEPO) and Darbepoetin, a long-acting EPO derivate. Furthermore, the demonstration of a cardiac production of EPO in Fugu rubripes and in Zebrafish has led cardiologists to “discover” Erythropoietin, postulating a hypothetical role in treatment of cardiovascular disease for this hormone. This is some of the experimental evidence which demonstrates that EPO can be in reason considered an important element of research of Regenerative Medicine and put in the network of drugs able to regenerate tissues and organs.
Keywords: Regenerative medicine, erythropoietin, angiogenesis
Current Pharmaceutical Design
Title: Regenerative Medicine: Does Erythropoietin have a Role?
Volume: 15 Issue: 17
Author(s): Michele Buemi, Antonio Lacquaniti, Giulia Maricchiolo, Davide Bolignano, Susanna Campo, Valeria Cernaro, Alessio Sturiale, Giovanni Grasso, Antoine Buemi, Alessandro Allegra, Valentina Donato and Lucrezia Genovese
Affiliation:
Keywords: Regenerative medicine, erythropoietin, angiogenesis
Abstract: Regenerative Medicine, a recent new medical domain, aims to develop new therapies through the stimulation of natural regenerative processes also in human beings. In this field, Erythropoietin (EPO) represents a significant subject of research. Several studies allow the assertion that EPO, in different concentrations, has protective effects mainly on the central nervous system, cardiovascular system and renal tissue. This action is carried out through one of few regenerative activities of human beings: angiogenesis. This mechanism, which involves endothelial stem cells and VEGF (Vascular Endothelial Growth Factor), has been experimentally demonstrated with Recombinant human erythropoietin (rHuEPO) and Darbepoetin, a long-acting EPO derivate. Furthermore, the demonstration of a cardiac production of EPO in Fugu rubripes and in Zebrafish has led cardiologists to “discover” Erythropoietin, postulating a hypothetical role in treatment of cardiovascular disease for this hormone. This is some of the experimental evidence which demonstrates that EPO can be in reason considered an important element of research of Regenerative Medicine and put in the network of drugs able to regenerate tissues and organs.
Export Options
About this article
Cite this article as:
Buemi Michele, Lacquaniti Antonio, Maricchiolo Giulia, Bolignano Davide, Campo Susanna, Cernaro Valeria, Sturiale Alessio, Grasso Giovanni, Buemi Antoine, Allegra Alessandro, Donato Valentina and Genovese Lucrezia, Regenerative Medicine: Does Erythropoietin have a Role?, Current Pharmaceutical Design 2009; 15 (17) . https://dx.doi.org/10.2174/138161209788453194
DOI https://dx.doi.org/10.2174/138161209788453194 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Medications for the Treatment of Alcohol Dependence: A Retrospective Study Conducted in 2011-2012
Current Drug Research Reviews Plant Polyphenols and Oral Health: Old Phytochemicals for New Fields
Current Medicinal Chemistry Role of microRNAs in Vascular Remodeling
Current Molecular Medicine Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design Role of Coronary Microvascular Endothelial Dysfunction in the Development of Heart Failure
Current Cardiology Reviews Nutritional and Therapeutic Potential of Spirulina
Current Pharmaceutical Biotechnology Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics Nutrition Status and Weight Management in Chinese Women
Current Women`s Health Reviews A Quantitative Structure-Activity Relationship Study on Some Series of Potassium Channel Blockers
Medicinal Chemistry Severe Coagulation Disorder and Thrombocytopenia Associated with Tigecycline – Case Report and Review of Literature
Current Drug Safety Renin-Angiotensin-Aldosterone System Antagonists and the Prevention of Type 2 Diabetes Mellitus
Current Pharmaceutical Design Transition of Care for Patients with Diabetes
Current Diabetes Reviews Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction: An Update
Recent Patents on Cardiovascular Drug Discovery Fondaparinux: Pharmacology and Clinical Experience in Cardiovascular Medicine
Mini-Reviews in Medicinal Chemistry Association Between Polycystic Ovary Syndrome and Metabolic Syndrome
Current Medicinal Chemistry Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Molecular Players at the Intersection of Obesity and Osteoarthritis
Current Drug Targets An Augmented Passive Immune Therapy to Treat Fulminant Bacterial Infections
Recent Patents on Anti-Infective Drug Discovery Use of Paediatric Xylometazoline Nasal Drop is not a Child’s Play in Hypertensive Patients on Bisoprolol: A Case Report
Current Drug Safety